Introduction
Glial cell line-derived neurotrophic factor (GDNF), a member transforming growth factor (TGF-) cytokine superfamily, is a homodimeric cytokine of disulphide-bridged N-glycosylated subunits, each 18-22kD . It is the prototypic member of a subfamily of four neurotrophic factors, the GDNF family ligands (GFLs), which also comprises artemin (ART), neurturin (NTN) and persephin (PSP) [1] . The GFLs exhibit high sequence homology and, in their canonical signaling pathway, share the cell surface tyrosine kinase Ret as the transmembrane signaling component of their receptor complexes [1] . The receptor complexes also contain a high affinity GPI-linked subunit, termed a GFR , with one GFR for each GFL; that for GDNF being GFR 1. Although limited cross-talk between some GFLs and GFR s has been reported [1], this may have little functional significance [2] . GDNF-GFR 1 interaction leads to engagement and activation of Ret BSA was added for 30min. After three washes in PBS-Tween, and two in PBS, wells were incubated with pnitrophenol solution, 100 l per well, at 37 o C in a shaking microtitre plate incubator. Absorbances at 405nm were read in an Emax plate reader (Molecular Devices, Sunnyvale, CA, USA) typically after 30min.
Uncoated but blocked wells containing substrate solution only were used as blanks. In a competitive variant of the ELISA, GFLs were preincubated with increasing concentrations of soluble heparin in PBS for 30min at room temperature, prior to addition to the coated ELISA wells.
Cloning and expression of GDNF
A plasmid, kindly provided by Dr Carlos Ibanez (Karolinska Institute, Stockholm) encoding the full-length sequence for wild-type rat GDNF precursor protein was digested with BamH1, and a 600bp product containing the coding sequence was extracted from a 1% agarose gel. The pFastBac1 vector (Invitrogen, Paisley, Scotland) was also digested with BamH1, and dephosphorylated with 1 international unit of calf intestinal alkaline phosphatase (Promega Corp., Southampton, UK) in restriction enzyme buffer. Treated vector, 100ng, was ligated with either 20 or 40ng of coding DNA using T4 DNA ligase (Fermentas, Helena Biosciences, Sunderland, Tyne and Wear), and transformed into DH5 1 E.Coli cells (Invitrogen). Plasmid DNA, isolated from resulting colonies was digested with BamH1 to confirm insertion, and clones were further selected for appropriate orientation of the insert according to the presence of a 300bp product after Pst1 digestion. The insert sequence was verified by nucleotide sequencing by of a PCR product generated by using using a forward primer, 5'-TCCGGATTATTCATACCGTCC -3', corresponding to a sequence on the 5' side of the multiple cloning site, and a reverse primer, 5'-ATGATCCTCTAGTACTTCTCG -3', just downstream of the multiple cloning site. A selected clone was then transformed into DH10Bac E.Coli cells (Invitrogen) according to the supplier's protocol. A single transformed colony was re-cloned and grown as a 200ml liquid culture in LB media containing selection antibiotics. The bacmid virus DNA was then isolated and stored at -20 o C. Sf9 insect cells (Invitrogen) were then transfected with the viral DNA following the supplier's protocols to produce a P1 virus, which was used to infect Sf9 cells to express the protein. 
Site-directed mutagenesis of GDNF
Two double point alanine substitution mutations, K83/K86 and R90/R92, and two partial deletions in the aminoterminal region, N 1 and N 2, were generated by overlap extension PCR. The mutagenesis primers used were as follows: K83/K86 forward, 5'-ATGTACGACGCAATACTAGCAAATCTGTCTCGAAGT-3'; K83/K86 reverse, ACTTCGAGACAGATTTGCTAGTATTGCGTCGTACAT; R90/R92 forward, CTGTCTGCAAGTGCAAGGCTAACAAGTGAC; R90/R92 reverse, GTCACTTGTTAGCCTTGCACTTGCAGACAG; N 1 forward, AAAGGTCACCAGATGAGAATTCCA; N 1 reverse, CTGGAATTCTCATCTGGTGACCTt; N 2 forward, GCTGCCAGCCCAGGGTGCGTCTTAA; N 2 reverse, TTAAGACGCACCCTGGGCTGGCAG.
In the case of the alanine substitutions, the mismatched codons are underlined. For each mutein, two PCR reactions were performed using the proof-reading polymerase Platinum Pfx (Invitrogen) on 1ng of GDNF wt DNA as template employing one of the mutagenesis primers with either the forward or reverse multiple cloning site primer as appropriate, with an initial cycle of 3mins at 92ºC, and 5mins at 55ºC, followed by 26 cycles of 30secs at 90ºC, 45secs at 55ºC and 90secs at 72ºC. The resulting amplified fragment was recovered from an agarose gel and purified. Paired fragments were then annealed in a second round of PCR using 10ng of each fragment and forward and reverse multiple cloning site primers. The product containing the full-length mutated GDNF cDNA was resolved on an agarose gel, purified, digested with BamHI and cloned in to pFastBac1 vector (Invitrogen).
Cloning and expression of soluble GFR -Flag
A plasmid encoding the extracellular domain of human GFR 1, splice variant 2, fused at Ile335 to a Flag tag sequence was digested with Xho1 and BamH1 and the 1400bp fragment containing the GFR 1 cDNA was extracted from a 1% agarose gel. The vector pFastBac1 was digested with the same endonuclease pair and dephosphorylated. The fragment was cloned in to the vector as described above and the insertion was verified by sequencing. Expression of the GFR 1 protein in Sf9 cells was then carried out as described for GDNF. 
Ion Exchange Chromatography
Conditioned supernatants from cultures expressing GDNF and variants thereof were dialysed against 25mM sodium phosphate buffer, pH 7.6, containing 5mM sodium EDTA. Dialysed supernatants, 50-100ml, were then applied at a flow rate of 5ml/h to 2.5ml bed volumes to SP-Trisacryl columns equilibrated in the same buffer. After a 5 bed vol. wash in buffer, a linear gradient 0-1.5M NaCl was applied. Fractions were assayed by heparin ELISA and Western blotting, and active fractions were pooled, dialysed against PBS and frozen.
Partial purification and concentration of GFR 1-Flag was achieved by dialysing conditioned supernatants (150-200ml) against 20mM Tris-HCl buffer, pH 8.5, containing 1mM EDTA, and applying to a Q-Sepharose Fast Flow column, 2ml, at a flow rate of 5ml/hr and eluted in a linear NaCl gradient. Fractions were analysed by anti-Flag captured ELISA, and positive fractions, which eluted at around 0.4M NaCl, were pooled and desalted into PBS on PD-10 columns.
Immunoassays of GDNF
Immunoblotting of GDNF was carried out by SDS PAGE electrophoresis on 15% (wt/vol) polyacrylamide gels. Gels were transblotted on to nitrocellulose membranes for 1h at 4ºC using 100V. After three 5min washes in TBS containing 0.05% (vol/vol) Tween 20, membranes were blocked in TBS/Tween containing 2% (wt/vol) dried skimmed milk powder. Membranes were then incubated overnight at 4ºC with rabbit anti-GDNF antibody diluted 1:500 in blocking buffer. After washing as above in TBS/Tween, membranes were incubated for 1h with affinity purified alkaline phosphatase-labelled anti-rabbit Ig (Jackson ImmunoResearch Laboratories, Inc. West Grove, PA 19390, USA) diluted 1/2000 in blocking buffer. After further washes in TBS/Tween, the membrane was developed by enhanced chemiluminescence. Dot-blotted nitrocellulose membranes were blocked and developed by the same method. ELISA of GDNF binding to immobilised GFR 1-Flag chimera were performed by coating plate wells with anti-FLAG monoclonal antibody diluted 1:500 in 30mM sodium bicarbonate buffer, pH 8.3, overnight at 4ºC. After washing the plate three times with PBS, wells were blocked with 2% (wt./vol) BSA in PBS for 30min. After washing 3 times in PBS, wells were incubated with 100 l/well partially purified GFR 1-Flag diluted 6.7-fold in blocking buffer. Plates were incubated for 2h, washed three times in PBS/Tween, and incubated for 1h with GDNF diluted in blocking buffer. After washing in PBS-Tween, plates were incubated for 1h with anti-GDNF diluted 1/200 in blocking buffer and washed again as previously. Wells were then incubated with alkaline phosphatase coupled anti-goat Ig, washed, and developed with p-nitrophenol phosphate as described above for the heparin binding ELISA.
ELISA of GFR 1-GDNF complexes
Complexes formed on the incubation of partially purified GFR 1-Flag with GDNF were assayed by a combination of the above assay protocols. Wells were coated with anti-Flag monoclonal antibody, washed and blocked with 2% (wt./vol) BSA in PBS. During this time appropriate quantities of GFR -Flag and GDNF were incubated in blocking buffer in the presence and absence of 2 g/ml heparin for 30min at room temperature. Wells were washed three times with PBS/Tween and 100 l aliquots of the incubation mixture were added for 2h. The wells were then washed, incubated with rabbit anti-GDNF and alkaline phosphatasecoupled second antibody as described for the GDNF ELISA.
Heparin Affinity Chromatography
Samples of recombinant GFLs, 500ng in the case of commercial rGDNF and equivalent immunoreactivities as adjudged by immunoblotting in the case of baculovirous expressed variants, dissolved in PBS were applied to HiTrap Heparin columns at a flow rate of 0.5ml/min. After eluting with 5ml PBS, a linear gradient of NaCl up to a final concentration of 1.5M was applied at the same flow rate. 1ml fractions were collected throughout.
Results
Previous work in this laboratory showed using a heparin binding ELISA that rhGDNF binds strongly to heparin and highly sulphated HS [21] . Here we investigated whether or not strong binding to heparin is a common feature of the GFLs. As may be seen in Fig 1a and b , both NTN and ART show strong, dosedependent binding to immobilised heparin-BSA complex, such binding being readily detectable with 0.5ng/well cytokine. By comparison there is only low, background binding of NTN and ART in control wells coated with mock-conjugated BSA. In order to confirm that the high binding to the heparin complex indeed arises by interaction with the GAG chains, we employed pre-incubation of sub-saturating amounts of the GFLs with increasing concentrations of soluble heparin prior to addition to the wells. As may be seen in We further investigated the heparin binding properties of GDNF, NTN and ART using affinity chromatography. As may be seen in Fig 2, all three GFLs bind tightly to the heparin column at physiological strength and pH, and elute as single peaks at high salt concentrations. Entirely consistent with the strong interaction of rhGDNF we found previously in the heparin ELISA [21] , rhGDNF elutes from the column at a comparatively high salt concentration of 0.8M NaCl. We found that NTN and ART reproducibly showed even stronger binding to the column, with peak elution respectively at 1.1 and 1.2M NaCl. These data confirm by an independent experimental procedure that these three GFLs bind strongly to heparin.
Since the primary sequences of all four GFLs show high homology, they should shed light on the location of the heparin binding sites. We first considered a cluster of basic residues on the exposed face of the -helix of GDNF. As has been previously noted, these form a prominent positively charged patch on the surface of GDNF [26] . Interestingly, NTN has a considerable cluster of basic charges in an equivalent region of its sequence (Fig 3) . We accordingly prepared two point substitution mutants of rat GDNF, in each of which two of the basically charged residues comprising this basic patch were replaced by alanine, as shown in 3. We termed these muteins K81/84, in which Lys81 and Lys84 were replaced in this way, and R88/90, in which Arg 88 and Arg90, were substituted.
Mature wild type rat GDNF and the K81/84 and R88/90 muteins were expressed in Sf9 insect cells. All three proteins were expressed as secreted dimers of anticipated M r , circa 40kD (data not shown). The GDNF immunoreactivity in the conditioned supernatants was concentrated and partially purified by ion-exchange chromatography on SP-Trisacryl. In each case the immunoreactivity bound to the column to be eluted by 0.6-1.0M NaCl. As may be seen in Fig This confirms that the ELISA immunoreactivity in the column eluate fractions arose from polypeptides of the appropriate molecular weight. We therefore conclude that the heparin binding affinity of GDNF is unaffected by these particular point substitutions.
Further consideration of the sequence of GDNF reveals that the comparatively long 40 residue aminoterminal sequence before the cysteine rich domain of GDNF is rich in basic residues, containing a total of 12 Args and Lys (Fig 3) . Of these, 11 may be considered to comprise two basic residue clusters, one of which has 4 Args in a hexapeptide sequence, and the other has 7 basic residues within a 13 residue sequence. NTN and ART have much shorter aminoterminal extensions, but both of these contain multiple arginines (Fig 3) . We therefore investigated the aminoterminal region of GDNF by preparing two partial deletion mutations, N 1 The two deletion mutants were similarly produced by baculovirus expression and partially purified by SP-Trisacryl ion exchange chromatography. On immunoblotting the two deletion mutants were again found to be dimers (data not shown), which under reducing and denaturing conditions ran as single bands with greater electrophoretic mobilities than wild type intact GDNF, entirely consistent with the predicted reduced masses ( Fig 5a) . As may be seen in Fig 5b, heparin-binding ELISA reveals that the N 1 mutant binds to the heparin complex in a manner indistinguishable from that of intact GDNF. By contrast, an equivalent immunoreactivity of N 2-GDNF, as adjudged by immunoblotting, fails to bind to the heparin complex in the ELISA.
On heparin affinity chromatography N 1 binds strongly to the heparin column and elutes at 0.8M NaCl (Fig5c), such behaviour being indistinguishable from that of intact GDNF (Fig 4b) . The presence of the N 1 mutant in these fractions was confirmed by dot blotting (data not shown). Since the N 2 mutant would be undetectable by heparin-binding ELISA (Fig 5b) , its elution was monitored solely by dot blotting. Such analysis reveals that N 2 also binds completely to the column, but in this case elution occurs at 0.3M NaCl (Fig 5d) , a level only just above physiological salt concentration, 0.18M. In the case of wild type GDNF and the two truncation mutants, Western blotting also confirmed that immunoreactivity was confined to the fractions positive on ELISA or dot blotting, and that under reducing conditions it migrated with M r s of circa 19kD (data not shown).
Since we have demonstrated that wild type GDNF binds strongly to heparin by two independent experimental approaches, we investigated how this interaction might affect the signaling activity of GDNF.
Taking FGF-2 as a prototypic example of a heparin binding growth factor, both cytokine and receptor bind to a heparin chain which thus cross-bridges between the two, stabilising their interaction [27, 28] . We therefore examined whether GFR 1, the high affinity GDNF receptor polypeptide, would also bind to heparin. Our initial studies employed a commercially obtained recombinant chimeric protein in which the extracellular domain of GFR 1 is fused to an Ig Fc domain and a carboxyterminal polyhistidine tag. This protein showed NaCl for its elution (data not shown). These observations raised the prospect that heparin-like glycosaminoglycan chains might indeed promote GDNF-receptor interactions. Because of the considerable biological significance of this possibility we examined this further. Since this chimeric polypeptide possesses a considerable amount of sequence not originating in the extracellular domain of the receptor, in particular an exposed polyhistidine tag, we expressed in a soluble construct of the extracellular domain of GFR 1 fused to a carboxyterminal Flag tag. We found that unlike the commercial chimera this construct does not bind at physiological strength and pH to the heparin-BSA complex in ELISA (data not shown).
Moreover on heparin affinity chromatography at physiological pH and ionic strength, GFR 1 eluted without retention in the break-through fractions as shown in Fig 6a. Since the GFR 1-Flag protein does not itself bind to heparin, we were able to employ it in the heparin binding ELISA to investigate whether GDNF retained on heparin is still able to bind to this receptor polypeptide. As may be seen in Fig 6b, heparin complex-coated wells incubated with GDNF are able to capture GFR 1-Flag as revealed strong immunoreactivity obtained after development with anti-Flag antibody (column c). By contrast there is little binding above background levels ( a and e) of GFRa1-Flag in the absence of GDNF, or in wells lacking heparin ( b and d respectively).
We sought to determine whether the recombinant GDNFs we had expressed were able to bind to the recombinant GFR 1-Flag, and how heparin might affect this interactions for both the wild type and truncated mutants. Therefore, comparable quantities of the partially purified GDNF and its variants, as adjudged by Western blotting, were incubated with a fixed amount of GFR 1-Flag prior to capture on anti-Flag coated wells. As may be seen in Fig 7 (solid bars) , wild type GDNF, and the N 1 and N 2 mutants all gave similar binding activities, indicating that neither deletion appreciably affects GFR 1 binding. Moreover addition of soluble heparin at 2 g/ml to the GFR 1-Flag and GDNF co-incubations neither substantially potentiates nor attenuates GFR 1-Flag binding to the wild type or truncated GDNFs (Fig 7, open bars) . The addition of soluble GFR 1 and GDNF to PC12 cells stimulates neurite outgrowth in a minority of the cells [29]. Since Davies et al. [23] showed that low concentrations of heparin are able to inhibit such outgrowth, we compared the activity of N 2 mutant with intact GDNF in this system. As seen in Fig 8a, cells grown in the absence of GDNF, but in the presence of soluble GFR 1-Fc show a very low spontaneous rate of neurite outgrowth, and where formed, these are of modest length. The further addition of recombinant wild-type GDNF causes a marked increase in the proportion of cells producing neurite outgrowth, although this remains a minority (Fig 8b) . Also more cells adopt a flattened morphology and many of the neurites formed are of considerable length. Because the cells form clumps in these cultures, the quantification of these effects is unreliable. The effects observed with the baculovirus expressed GDNF are fully consistent in nature and extent with those we obtained with the commercial recombinant GDNF (data not shown). The N 2 variant was similarly active in promoting these effects (Fig 8c) . Heparin at 1 g/ml completely inhibits the neurite outgrowth induced by the wild type GDNF expressed in the baculovirus system (Fig 8d) , as previously reported elsewhere for commercial recombinant GDNF [23] . Somewhat surprisingly the same total inhibition by heparin was also observed with the N 2 variant (Fig 8e) , despite its considerably reduced affinity for heparin.
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Discussion
Having previously investigated the binding of GDNF to heparin and related polysaccharides, we show here by both ELISA and affinity chromatography that two other GFLs, ART and NTN, also bind heparin. Indeed higher salt concentrations are required for the elution of ART and NTN from the heparin column than for GDNF. Since the interaction between polypeptides and sulphated GAGs is largely polyionic [30] , our results reveal within the GFLs heparin affinity increases in the order GDNF<NTN<ART. A key finding of this study is that the major determinant of heparin binding is located within a 16 residue sequence which contains 7 Args and Lys, and is located immediately aminoterminal to the TGF-type cysteine knot domain. The unusually long, 40 residue aminoterminal extension to the cysteine knot domain in GDNF is not resolved its high resolution structure [31] , which precludes structural modelling of this interaction. Thus it is not possible to suggest whether or not the two N 2 sequences in a GDNF dimer might combine to give a single joint site.
The more aminoterminal sequence deletion, N 1, has no effect on heparin binding. This is somewhat surprising as it might be more exposed, and it contains a BBXB motif which is often advocated as a heparin binding motif [32] . We also show that double alanine substitutions of basic residues in and around the shorthelix, a region of prominent basic charge [26] , have no effect on heparin binding.
The N 2 mutant fails to bind in the ELISA, but binds to the heparin affinity column, despite the fact that both procedures are conducted at physiological pH and ionic strength. However N 2-GDNF is eluted from the heparin column by only a marginal increase in salt concentration demonstrating that binding affinity is very weak. The different observations from these two experimental approaches may arise from the heparin involved being from different sources, or having been subjected to different coupling methods. It might also arise from the greater degree of mechanical disturbance of binding during ELISA plate washes, compared to the slow and uniform flow of eluant in the columns. Alternatively, since the heparin affinity column matrix contains a high concentration of heparin chains, which in turn have dense arrays of strongly anionic groups, the residual heparin binding to the affinity matrix may simply represent a non-specific, weak ion-exchange interaction, bearing in mind that the N 2 variant like intact GDNF exhibits unchanged binding affinity for the sulphopropyl moiety in the ion exchange resin used for their partial purification.
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During the course of this work, a structural study of ART has revealed that it has a high affinity for heparin [33] . These workers found that deletion of the first 9 aminoterminal residues, which includes two basic residues and corresponds partially to the N 2 sequence of GDNF, resulted in a substantial decrease in heparin binding. They further showed that a BBXB motif, Arg-Arg-Ala-Arg, close to the -helix was also an important determinant of heparin binding of the unglycosylated ART they studied [33] . This implies the existence of a discontinous binding site encompassing the aminoterminus and this BBXB motif, but again lack of resolution of the aminoterminus in their crystallographic structure of ART precludes full insight. This central BBXB motif is absent from GDNF, indeed one of the corresponding residues in the latter is the acidically charged aspartate. Taking our findings together with these, we propose that basic residues lying immediately aminoterminal to the cysteine knot in a flexible region of the polypeptide are major determinants of heparin binding in the GFLs. However there has been some evolutionary divergence of heparin binding sites, such that in ART a further basically charged motif central in this polypeptide, but absent from GDNF, is also involved. The weak heparin binding we observe with the N 2-GDNF mutant in heparin chromatography means we cannot preclude the possible involvement of additional sites within GDNF. The importance of basic residue clusters immediately aminoterminal to the cysteine rich TGF-type domain in heparin binding is also seen in the related cytokines bone morphogenetic proteins (BMPs) -2 [34] and -4 [35] .
The prototypic and arguably best understood example of a cytokine-GAG interaction is the heparin binding of FGF-2. Heparin/HS is essential for FGF-2 signalling, and high resolution structures of the FGF receptor-FGF-heparin complexes show heparin stabilising the complex by cross-bridging the cytokine to its receptor [27, 28] , and in one case also cross-bridging the two FGF-FGF receptor pairs in the tetrameric assembly [27] . receptor cross-bridging. Despite the fact that we found a commercial His-tagged GFR 1-Fc chimeric protein binds strongly to heparin, we show here that a soluble recombinant protein comprising the extracellular domain of GFR 1-fused to a carboxyterminal Flag tag shows no such binding. This protein binds GDNF and is active in a standard cellular bioassay for GDNF signalling at levels comparable to the commercial chimera (data not shown), indicating correct folding. Our results preclude the possibility that heparin/HS can cross-bridge GDNF to its high affinity receptor protein. Therefore the GAG binding of the GFR 1-Fc chimera must arise from either the Fc domain or polyHis tag to which it is fused. Since there is no record of GAG binding within the human IgG 1 Fc domain involved, it is very likely that it is the latter polybasic sequence which introduces an artefactual heparin binding site. This phenomenon has been previously reported [37] , and suggests that the characterization of GAG binding of recombinant proteins bearing a polyHis tag is unreliable.
GDNF captured on heparin is still able to bind GFR 1-Flag. This finding is of some physiological significance, since it suggests that GDNF immobilized on heparin-like chains does not need to be released in order to engage GFR 1, the first step in its signaling pathway. It also shows that the heparin binding site on GDNF is physically distinct from its GFR 1 binding sites such that the one interaction does not prevent the other. Since the GFR 1 binding sites are located on the exposed tips of finger-like -stranded loops [26] , which are distant from the aminoterminii of the subunits this result is consistent with our localisation of the major determinant of heparin binding.
We show here that GDNF mutants with aminoterminal truncations bind to GFR 1 and trigger cellular response normally. The binding of wild type GDNF and the truncated variants thereof to soluble GFR 1 is essentially neither inhibited nor potentiated by soluble heparin, indicating that heparin binding plays no role in this interaction. We previously reported a modest potentiation of GDNF binding to surface-captured GFR 1-Fc [21] , and we also observed this in the current work in some experiments when high concentrations of GDNF were employed. However we cannot now exclude the possibility that under these particular conditions, multiple GDNF molecules may bind to a heparin chain, thus the receptor engagement It has been shown that soluble heparin at low concentration inhibits GDNF activity in several culture systems, and that selective 2-O-desulphation of the heparin blocks this effect, whereas other modifications do not [23] . This finding fits well with a model in which GDNF activity is dependent on binding to 2-Osulphate rich heparin-like GAG for its physiological activity. Here we show that a GDNF variant in which heparin affinity is markedly reduced still binds normally to a soluble construct of its high affinity receptor polypeptide, and that this interaction is unaffected by the presence of heparin. However the activity of this GDNF variant in cell culture still remains sensitive to the presence of heparin. These findings indicate that the effect of heparin/HS on GDNF activity lies elsewhere than its interaction with GFR 1, and that other cell surface events in GDNF signaling require scrutiny in order to reveal the mechanism for the GAG-dependence of GDNF activity. 
Figure Legends
